Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Zelira Therapeutics Ltd

ZLD.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Pharmaceuticals ·

Australia Micro Cap Analyst: BUY

Last Close

$0.36

▲ +0.00%

Market Cap $4.64M · Vol 19.14K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$4.64M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

50.00

Momentum

Beta

1.17

vs Market

52W High

$0.81

53.93% below

52W Low

$0.22

74.30% above

Volume

19.14K

Avg 0

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

43.30%

Public shares

Shariah Compliance8 STANDARDS

✗ Zelira Therapeutics Ltd (ZLD.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ZLD.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-18.03%

YTD

+17.65%

+19.05%

-63.26%

-93.20%

Financials & Valuation

TTM · Annual

Total Revenue	$434.00
Net Income	$-2,533,078.00
Revenue Growth (YoY)	-100.00%
Gross Margin	-42,476.98%
Operating Margin	-580,710.82%
Net Profit Margin	-586,840.24%
ROE	N/A
ROA · ROIC	-118.74% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	7,702.11
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	13.15M

Technical Indicators

50-Day SMA	$0.35
200-Day SMA	$0.34
RSI (14)	50.00
Beta	1.17
52-Week High	$0.81
52-Week Low	$0.22

Volume Today	19.14K
Avg Daily Volume (30D)	0
Relative Volume	N/Ax
Volatility (10D)	0.00
Volatility (30D)	0.00
Free Float	43.30%

Analyst Consensus

BUY

Current Price $0.36

Mean Target N/A

52W Low$0.22 52W High$0.81

Current

Target

$0.22 $0.81

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG001SJGQT9

ISINAU000000ZLD1

CountryAustralia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development to enter global markets. It is focused on developing and clinically validating cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company is in partnership with SprinJeneCBD, introduced a full line of oral care products. Its RAFFIVE brand, which consists of five over-the-counter acne treatment products using a proprietary formulation incorporating cannabidiol (CBD).